| 1 |
31645440 | A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. | 2020 Feb |
3 |
| 2 |
32366411 | Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation. | 2020 May |
3 |
| 3 |
29059158 | RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. | 2018 Feb 8 |
3 |
| 4 |
30118796 | Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. | 2018 Sep |
1 |
| 5 |
27999210 | LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. | 2017 Feb 7 |
1 |
| 6 |
28382170 | Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer. | 2017 |
1 |
| 7 |
28576749 | A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. | 2017 Aug 28 |
1 |
| 8 |
26732095 | Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. | 2016 Mar |
8 |
| 9 |
26343583 | Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. | 2015 Sep 14 |
6 |